A batch enters Germany through six steps: cultivation, post-harvest, EU-GMP processing, licensed import, GDP wholesale, and pharmacy.[3][7][6] The route looks agricultural at the start and pharmaceutical by the time it reaches the patient.
The turn happens at the processor. That is where flower from a GACP farm enters a manufacturing system with controlled records, QA review, and later QP release.[5][8][9]
Germany imported 201,094 kg in 2025 and still had only three domestic producers.[1][2] The route is therefore built around cross-border manufacturing and release capacity, not around domestic cultivation alone.
The processor gate decides whether cultivation can become a medical file
A GACP farm can produce clean flower and still arrive at the wrong gate with the wrong package. The processor is reading admissibility, methods, traceability, document control, and whether the batch can enter a manufacturing route that will later support QP release.[8][9]
That is why the route turns there. The batch stops being only an origin story and starts being a pharmaceutical record under someone else's quality system.[5][3]
"The batch becomes a German-facing medical product at the processor step."— AMG manufacturing rules, Annex 16, and BfArM trader guidance
Processing hubs show where the route currently exits
BfArM's 2025 country table put Portugal at 55,164 kg and Malta at 4,858 kg, alongside Germany's own medical-cannabis route.[1] Those figures sit inside the import file, though they also show how often the route exits through established EU-GMP processing jurisdictions before it reaches a German importer.
The country chart records movement into Germany. Cultivation origin follows a separate line through the operating file once the batch has passed through manufacturing and release.[1][3]
Germany reads the route through licenses, approvals, and named counterparties
BfArM's trader guidance for § 4 MedCanG asks the trader to identify products, origin, grower, source, operating sites, and responsible parties.[3][4] The import leg then sits under § 72 AMG, and the downstream wholesale leg sits under § 52a AMG.[7][6]
Those requirements explain why the processor relationship matters so much. The German importer stands behind a named file that has already passed through manufacturing, release, and import control.[3][9]
Toll processing exists because market entry and full site build run on different clocks
The farm may be ready to cultivate before it is ready to operate a full EU-GMP manufacturing system on site. The toll-processing route separates those clocks. The processor holds the manufacturing authorization and release discipline while the farm supplies the batch into that system.[5][9]
That route gives the farm a current path into Germany while the farm keeps building the tighter records, methods, and site controls that later EU-GMP readiness would require.[8][3]
The processor is reading several layers at once
The batch package has to hold across cultivation records, post-harvest handling, sampling, methods, deviations, and current document versions.[8] Annex 16 then ties release to a controlled manufacturing and certification file.[9]
That sequence is why farms often feel closer to Germany than they really are. The first visible distance is geographic. The harder distance sits inside the quality file.
The chain is easier to read in order
First comes a batch that can enter the processor file. Then comes manufacturing discipline, QP release, import approval, wholesale control, and pharmacy supply.[5][9][7][6]
A later step does not rescue an earlier one. A willing buyer does not repair a weak batch package. An import permit does not repair a release file that never held together.
This step controls more time than the farm usually expects
The processor review can reopen questions on methods, record structure, and retained material before the German importer ever books saleable stock.[8][3] When demand is moving quickly, that delay becomes commercial rather than purely technical.
Germany's 2025 import volume shows why time matters. A batch that misses its release window is landing into a market with more product, tighter pricing, and less patience for rework.[1]
The public origin table and operating record answer different questions
BfArM's published country totals are useful market data.[1] The operating record still has to keep cultivation origin legible after processing, because the trader submission names the product, origin, grower, and source.[3]
That is why origin can look smaller in public charts than it feels inside the file. The public table counts where the released product entered Germany. The internal record still has to remember where the batch began.
The processor is where the route becomes real
Primary Sources
- BfArMMedizinalcannabisverkehr – Ein-/Ausfuhr↗
- BfArMFAQ Medizinisches Cannabis↗
- BfArMHinweise fuer Haendler nach § 4 MedCanG (Stand 09/25)2025-09↗
- Gesetze im InternetMedizinal-Cannabisgesetz (MedCanG)↗
- Gesetze im InternetArzneimittelgesetz § 13 - Herstellungserlaubnis↗
- Gesetze im InternetArzneimittelgesetz § 52a - Erlaubnis fuer den Grosshandel↗
- Gesetze im InternetArzneimittelgesetz § 72 - Einfuhrerlaubnis↗
- European CommissionEudraLex Volume 4 - Chapter 4 Documentation↗
- European CommissionEudraLex Volume 4 - Annex 16 Certification by a Qualified Person and Batch Release↗